Tobias Walbert1, Rebecca A Harrison2, David Schiff3, Edward K Avila4, Merry Chen2, Padmaja Kandula5, Jong Woo Lee6, Emilie Le Rhun7, Glen H J Stevens8, Michael A Vogelbaum9, Wolfgang Wick10, Michael Weller11, Patrick Y Wen12, Elizabeth R Gerstner13,14. 1. Department of Neurology and Neurosurgery, Henry Ford Health System and Wayne State University, Detroit, Michigan, USA. 2. Department of Neuro-oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 3. Department of Neurology, University of Virginia Health System, Charlottesville, Virginia, USA. 4. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 5. Division of Clinical Neurophysiology and Epilepsy, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, USA. 6. Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA. 7. Department of Neurology and Neurosurgery, Brain Tumor Center & Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland. 8. Rose Ella Burkhardt Brain Tumor and Neuro-oncology Center, Cleveland Clinic, Cleveland, Ohio, USA. 9. Department of NeuroOncology, Moffitt Cancer Center, Tampa, Florida, USA. 10. Neurology Clinic and Neurooncology Program, Heidelberg University and German Cancer Research Center, Heidelberg, Germany. 11. Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland. 12. Center For Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 13. Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA. 14. Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
OBJECTIVE: To update the 2000 American Academy of Neurology (AAN) practice parameter on anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. METHODS: Following the 2017 AAN methodologies, a systematic literature review utilizing PubMed, EMBASE Library, Cochrane, and Web of Science databases was performed. The studies were rated based on the AAN therapeutic or causation classification of evidence (class I-IV). RESULTS: Thirty-seven articles were selected for final analysis. There were limited high-level, class I studies and mostly class II and III studies. The AAN affirmed the value of these guidelines. RECOMMENDATIONS: In patients with newly diagnosed brain tumors who have not had a seizure, clinicians should not prescribe antiepileptic drugs (AEDs) to reduce the risk of seizures (level A). In brain tumor patients undergoing surgery, there is insufficient evidence to recommend prescribing AEDs to reduce the risk of seizures in the peri- or postoperative period (level C). There is insufficient evidence to support prescribing valproic acid or levetiracetam with the intent to prolong progression-free or overall survival (level C). Physicians may consider the use of levetiracetam over older AEDs to reduce side effects (level C). There is insufficient evidence to support using tumor location, histology, grade, molecular/imaging features when deciding whether or not to prescribe prophylactic AEDs (level U).
OBJECTIVE: To update the 2000 American Academy of Neurology (AAN) practice parameter on anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. METHODS: Following the 2017 AAN methodologies, a systematic literature review utilizing PubMed, EMBASE Library, Cochrane, and Web of Science databases was performed. The studies were rated based on the AAN therapeutic or causation classification of evidence (class I-IV). RESULTS: Thirty-seven articles were selected for final analysis. There were limited high-level, class I studies and mostly class II and III studies. The AAN affirmed the value of these guidelines. RECOMMENDATIONS: In patients with newly diagnosed brain tumors who have not had a seizure, clinicians should not prescribe antiepileptic drugs (AEDs) to reduce the risk of seizures (level A). In brain tumor patients undergoing surgery, there is insufficient evidence to recommend prescribing AEDs to reduce the risk of seizures in the peri- or postoperative period (level C). There is insufficient evidence to support prescribing valproic acid or levetiracetam with the intent to prolong progression-free or overall survival (level C). Physicians may consider the use of levetiracetam over older AEDs to reduce side effects (level C). There is insufficient evidence to support using tumor location, histology, grade, molecular/imaging features when deciding whether or not to prescribe prophylactic AEDs (level U).
Authors: Rohit R Das; Elinor Artsy; Shelley Hurwitz; Patrick Y Wen; Peter Black; Alexandra Golby; Barbara Dworetzky; Jong Woo Lee Journal: J Neurooncol Date: 2012-01-03 Impact factor: 4.130
Authors: J A French; A M Kanner; J Bautista; B Abou-Khalil; T Browne; C L Harden; W H Theodore; C Bazil; J Stern; S C Schachter; D Bergen; D Hirtz; G D Montouris; M Nespeca; B Gidal; W J Marks; W R Turk; J H Fischer; B Bourgeois; A Wilner; R E Faught; R C Sachdeo; A Beydoun; T A Glauser Journal: Neurology Date: 2004-04-27 Impact factor: 9.910
Authors: Peter A Forsyth; Susan Weaver; Dorcas Fulton; Penelope M A Brasher; Garnette Sutherland; Doug Stewart; Neil A Hagen; Penny Barnes; J Greg Cairncross; Lisa M DeAngelis Journal: Can J Neurol Sci Date: 2003-05 Impact factor: 2.104
Authors: Ayal A Aizer; Nayan Lamba; Manmeet S Ahluwalia; Kenneth Aldape; Adrienne Boire; Priscilla K Brastianos; Paul D Brown; D Ross Camidge; Veronica L Chiang; Michael A Davies; Leland S Hu; Raymond Y Huang; Timothy Kaufmann; Priya Kumthekar; Keng Lam; Eudocia Q Lee; Nancy U Lin; Minesh Mehta; Michael Parsons; David A Reardon; Jason Sheehan; Riccardo Soffietti; Hussein Tawbi; Michael Weller; Patrick Y Wen Journal: Neuro Oncol Date: 2022-10-03 Impact factor: 13.029
Authors: Elias Konrath; Franz Marhold; Wolfgang Kindler; Florian Scheichel; Branko Popadic; Katrin Blauensteiner; Bernadette Calabek; Elisabeth Freydl; Michael Weber; Robin Ristl; Katharina Hainz; Camillo Sherif; Stefan Oberndorfer Journal: BMC Neurol Date: 2022-07-08 Impact factor: 2.903
Authors: María Martínez-García; Sonia Servitja Tormo; Noelia Vilariño Quintela; Ana Arance Fernández; Alfonso Berrocal Jaime; Blanca Cantos Sánchez de Ibargüen; Sonia Del Barco Berrón; Rosario García Campelo; Regina Gironés Sarrió; Juan Manuel Sepúlveda-Sánchez Journal: Clin Transl Oncol Date: 2022-03-08 Impact factor: 3.405